MXPA05012467A - Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie. - Google Patents

Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.

Info

Publication number
MXPA05012467A
MXPA05012467A MXPA05012467A MXPA05012467A MXPA05012467A MX PA05012467 A MXPA05012467 A MX PA05012467A MX PA05012467 A MXPA05012467 A MX PA05012467A MX PA05012467 A MXPA05012467 A MX PA05012467A MX PA05012467 A MXPA05012467 A MX PA05012467A
Authority
MX
Mexico
Prior art keywords
coated
immunosuppressive
anticonvulsant
surface modifiers
solid particles
Prior art date
Application number
MXPA05012467A
Other languages
English (en)
Inventor
Jamie Teresa Konkel
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of MXPA05012467A publication Critical patent/MXPA05012467A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction

Abstract

Esta invencion se refiere a la formulacion de suspensiones de particula pequena de anti-convulsivos, particularmente carbamazepina, para uso farmaceutico. Esta invencion tambien se refiere a la formulacion de una suspension de particula pequena de agentes inmunosupresores, particularmente ciclosporina, para uso farmaceutico. Las particulas se revisten con uno o mas modificadores de superficie.
MXPA05012467A 2003-05-19 2004-05-19 Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie. MXPA05012467A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47158103P 2003-05-19 2003-05-19
PCT/US2004/015621 WO2004103348A2 (en) 2003-05-19 2004-05-19 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers

Publications (1)

Publication Number Publication Date
MXPA05012467A true MXPA05012467A (es) 2006-02-22

Family

ID=33476859

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012467A MXPA05012467A (es) 2003-05-19 2004-05-19 Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.

Country Status (11)

Country Link
US (1) US20050244503A1 (es)
EP (1) EP1628641A2 (es)
JP (1) JP2006528985A (es)
KR (1) KR20060012628A (es)
CN (1) CN1791386A (es)
AU (1) AU2004240640A1 (es)
BR (1) BRPI0410767A (es)
CA (1) CA2524538A1 (es)
MX (1) MXPA05012467A (es)
NO (1) NO20056020L (es)
WO (1) WO2004103348A2 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025918A1 (en) * 1995-02-24 1996-08-29 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
WO2000018374A1 (en) * 1998-10-01 2000-04-06 Elan Pharma International, Ltd. Controlled release nanoparticulate compositions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
CA2461349C (en) 2001-09-26 2011-11-29 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
CA2475092C (en) 2002-02-04 2012-05-01 Christian F. Wertz Nanoparticulate compositions having lysozyme as a surface stabilizer
CA2513064C (en) * 2003-01-31 2009-11-10 Elan Pharma International, Ltd. Nanoparticulate topiramate formulations
US20040208833A1 (en) * 2003-02-04 2004-10-21 Elan Pharma International Ltd. Novel fluticasone formulations
CA2540695A1 (en) * 2003-06-24 2004-12-29 Baxter International Inc. Specific delivery of drugs to the brain
US8986736B2 (en) * 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US7824697B2 (en) 2004-07-12 2010-11-02 Board Of Regents, The University Of Texas System High concentration baclofen preparations
JP2008524239A (ja) * 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミティド ナノ粒子のタクロリムス製剤
KR20070121758A (ko) * 2005-03-17 2007-12-27 엘란 파마 인터내셔널 리미티드 나노입자형 면역 억제 화합물의 주사가능한 조성물
CN101171000A (zh) * 2005-04-12 2008-04-30 依兰药物国际有限公司 包含环孢菌素的毫微粒和控制释放组合物
BRPI0607537A2 (pt) * 2005-04-12 2009-09-15 Elan Pharma Int Ltd formulações de derivado de quinazolina nanoparticulado
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
BRPI0600285C1 (pt) * 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
EP2173327A2 (en) * 2007-07-24 2010-04-14 Nexbio, Inc. Technology for the preparation of microparticles
US9364443B2 (en) * 2008-03-05 2016-06-14 Baxter International, Inc. Compositions and methods for drug delivery
US20150258279A1 (en) 2008-03-18 2015-09-17 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms and related delivery system
US8969414B2 (en) 2009-02-06 2015-03-03 Mallinckrodt Llc Intrathecal baclofen pharmaceutical dosage forms with fewer degradation products
US10952965B2 (en) * 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
NZ601109A (en) 2009-12-10 2014-06-27 Merck Patent Gmbh Pharmaceutical composition comprising oligopeptides, preferably cilengitide
WO2012039979A2 (en) * 2010-09-10 2012-03-29 The Johns Hopkins University Rapid diffusion of large polymeric nanoparticles in the mammalian brain
WO2012167870A1 (en) 2011-06-09 2012-12-13 Merck Patent Gmbh Treatment of cancers and metastases with suspensions of cilengitide in carrier
US20140178479A1 (en) 2011-08-12 2014-06-26 Perosphere, Inc. Concentrated Felbamate Formulations for Parenteral Administration
EP2866792A4 (en) 2012-06-28 2016-08-17 Ansun Biopharma Inc MICROPARTICLE FORMULATIONS FOR DELIVERY TO LOWER AND CENTRAL RESPIRATORY PATHS AND METHOD OF PREPARING THEM
CA2890219A1 (en) * 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
JP6491203B2 (ja) 2013-10-25 2019-03-27 インスメッド インコーポレイテッド プロスタサイクリン化合物、組成物およびその使用方法
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
KR20180082457A (ko) * 2015-10-16 2018-07-18 마리누스 파마슈티컬스 인코포레이티드 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들
CA3060255A1 (en) * 2017-04-18 2018-10-25 Marinus Pharmaceuticals, Inc Sustained release injectable neurosteroid formulations
WO2019186515A1 (en) * 2018-03-30 2019-10-03 Ftf Pharma Private Limited Liquid pharmaceutical compositions of antiepileptic drugs
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) * 1960-08-09 New n-heterocyclic compounds
US4608278A (en) * 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1338736C (fr) * 1986-12-05 1996-11-26 Roger Baurain Microcristaux comportant une substance active presentant une affinite pour les phospholipides, et au moins un phospholipide, procede de preparation
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
GB9024366D0 (en) * 1990-11-09 1991-01-02 Glaxo Group Ltd Medicaments
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5720551A (en) * 1994-10-28 1998-02-24 Shechter; Tal Forming emulsions
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
US5716642A (en) * 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
ES2208946T3 (es) * 1996-08-23 2004-06-16 Sequus Pharmaceuticals, Inc. Liposomas que contienen un compuesto de cisplatino.
PT954282E (pt) * 1997-01-16 2005-06-30 Massachusetts Inst Technology Preparacao de particulas para inalacao
ES2257041T3 (es) * 1998-03-30 2006-07-16 Jagotec Ag Composicion y metodo para preparar microparticulas de substancias insolubles en agua.
NZ507619A (en) * 1998-04-18 2003-05-30 Glaxo Group Ltd Pharmaceutical aerosol formulation with liquefied propellant gas
US6270806B1 (en) * 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
WO2000061108A1 (en) * 1999-04-14 2000-10-19 Glaxo Group Limited Pharmaceutical aerosol formulation
US6395300B1 (en) * 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20060003012A9 (en) * 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems

Also Published As

Publication number Publication date
KR20060012628A (ko) 2006-02-08
EP1628641A2 (en) 2006-03-01
AU2004240640A1 (en) 2004-12-02
CN1791386A (zh) 2006-06-21
WO2004103348A3 (en) 2005-01-06
BRPI0410767A (pt) 2006-07-04
JP2006528985A (ja) 2006-12-28
WO2004103348A2 (en) 2004-12-02
CA2524538A1 (en) 2004-12-02
US20050244503A1 (en) 2005-11-03
NO20056020L (no) 2005-12-16

Similar Documents

Publication Publication Date Title
MXPA05012467A (es) Particulas solidas que comprenden un anticonvulsivo o un inmunosupresor revestido con uno o mas modificadores de superficie.
AU2002365875A1 (en) Stent designed for the delivery of therapeautic substance or other agents
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
WO2005005679A3 (en) Super-hydrophobic surfaces, methods of their construction and uses therefor
TW200732349A (en) Anti-OX40L antibodies and methods using same
LUC00065I2 (es)
TW200420573A (en) Bifunctional heterocyclic compounds and methods of making and using same
MXPA03001001A (es) Derivados anticonvulsionantes utiles para el tratameinto de la depresion.
WO2006115847A3 (en) Coated endoprostheses
WO2007136893A3 (en) Anti-fgf19 antibodies and methods using same
WO2006071693A3 (en) Injectable non-aqueous suspension
WO2003047420A3 (en) Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
TW200510002A (en) Solid pharmaceutical preparation
AU2003300801A1 (en) Dynamic coupons
WO2007056625A3 (en) Thienopyridine b-raf kinase inhibitors
TW200621160A (en) Anti-termite agent
RS97604A (en) New etonogestrel esters
NL1020632A1 (nl) Werkwijze voor de productie van brandstof uit een Fischer-Tropsch- proces.
WO2006060542A3 (en) Formulations of substituted benzoxazoles
AU2003228236A1 (en) Dynamic time metered delivery
MA29492B1 (fr) Formulations stables de nanoparticules
TW200501964A (en) Lipid-regulating agent and its usage
WO2004037168A3 (en) Treatment of pancreatitis with amylin
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
AU2001256299A1 (en) Improved painting booth, preferably of the electrostatic painting type

Legal Events

Date Code Title Description
FA Abandonment or withdrawal